The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets

At their most basic level, wellness programs represent an attempt to encourage good health and thereby decrease utilization of health care products and services. They have evolved out of necessity from the current U.S. health care system, in response to a variety of factors including continually rising costs of care and declining quality of life.

A Comprehensive Look at the ‘Wellness’ Industry

Utilization of wellness programs in the United States has experienced strong recent growth this is expected to continue through the forecast period. As more people participate in wellness programs, their usage of various health care products and services will be affected, as well the revenues of wellness program providers. This report looks at the emerging wellness industry and estimates the market for wellness related products and services. This portion of the report examines:

• Drivers of Wellness Services
• Utilization Statistics
• Major Companies and Offerings
• Current Wellness Program Market Size
• Innovative Approaches
• Results of Programs
• General Trends (Weak U.S. Economy, Postponing of Retirement, EMR, Rising Interest in Anti-Aging)
• Industry Trends (Internet-Based Wellness Programs, Usage of Financial Incentives, Emergence of Retail Clinics)

A Report No Pharmaceutical, Device or Testing Product Marketer Should Be Without

If wellness programs are effective, there should be an impact on all healthcare industries: pharmaceuticals, devices and diagnostics. Positive impact for some, negative for others. As part of Kalorama’s unique analysis on this topic, this report also takes a look at how the popularity of wellness programs will effect other markets. The report estimates the positive or negative sales impact of wellness programs upon established U.S. markets for various health care products and services including:

• Allergy Medicines
• Cholesterol Reducers
• Diabetes Drugs
• Gastrointestinal Medications/Proton Pump Inhibitors
• Hypertension Medicines
• Over-the-Counter (OTC) Medicines
• Influenza Vaccines
• Cervical Cancer Vaccines
• Diagnostic Tests
• Cardiovascular, Gastric Banding, and other Devices
• Surgeries,
• Imaging
• Other Medical Services

Within each of these market segments, products, services and/or sub-segments were selected that will particularly be affected by wellness programs. Products, services and/or sub-segments that are not expected to be significantly impacted were not included.

Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are provided for the historic 2004 – 2008 period and forecasts are provided through 2013. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

For more information, please visit :
http://www.aarkstore.com/reports/The-Market-for-Wellness-Programs-and-Their-Impact-on-Pharmaceutical-Diagnostic-and-Device-Product-Markets-31211.html
Or email us at press@aarkstore.com or call +919272852585

Obesity, Weight Loss and Diet Management Markets (Pharmaceutical, Surgical and Dietary Approaches)

Weight loss and diet management is a challenge for millions of people around the world. Globally, more than 1 billion people are above an ideal weight. The affects weight has on life-threatening or life-altering disease are devastating. Diseases such as diabetes, heart disease, and cancer all have links to being overweight or obese.

Increasing education efforts, accessible weight management plans and foods, and a growing desire to be physically desirable have fueled this market in more recent years. More than 100 million people in the United States are actively involved in a weight loss or weight management plan at any one time throughout the year. This suggests a demand for products and services which will continue for years to come. This Kalorama Information report – Obesity, Weight Loss and Diet Management Markets – focuses on five key segments of products, treatments, and services:

• Diet Foods and Drinks (Drinks and powders, Bars and Snacks, Meals, Desserts)
• Weight Loss Drugs (Prescription Drugs, OTC)
• Natural Therapies for Weight Loss
• Surgical Interventions (Gastric Banding, Other)
• Weight Loss Programs (Revenues from Delivered Food, Revenues From Program Fees)

The report includes statistical information for obesity and higher body mass worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, market estimates and forecasts, and trends in the industry. Trends discussed in the report include:

• Weight Loss Incentives in the Work Environment
• Healthy Lifestyle and American Cancer Society
• Outlook for a Healthier U.S. Population
• Childhood Obesity
• Inadequate Levels of Sleep, Technology, Caffeine, and the Affect on Adolescents
• Weight Loss Camps and Schools
• Factors that Affect Weight Among Adolescent Girls
• ‘Smart Choices Program’
• New Developments in Pharmaceutical Weight Loss
• New Developments in Weight Loss Surgical Devices
• Trends in Bariatric Surgery
• Obesity Trends During Socioeconomic Changes
• Discontinued Weight Loss Drugs

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering primary information.

For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue data presented in this report. All market data pertains to the world market at the manufacturers’ level. The base year for data was 2009. Historical data was provided for the years 2006 through 2008, with forecast data provided for 2010 through 2013. Compound annual growth rates (CAGRs) are provided for the 2006-2009, 2009-2013 and 2006-2013 periods for each segment covered.

The forecasted market analysis for 2010-2013 was based on probability of drug approval and sales of products in late stage development, future trends in current product demand, obesity statistics and trends, product marketing, and relevant demographic trends.

For more information, please visit :
http://www.aarkstore.com/reports/Obesity-Weight-Loss-and-Diet-Management-Markets-Pharmaceutical-Surgical-and-Dietary-Approaches–34623.html
Or email us at press@aarkstore.com or call +919272852585

The Global OTC Pharmaceutical Market 2009-2024

OTC pharma is influenced by changes in consumer spending – but significant commercial opportunities for OTC switching will drive market expansion worldwide – our new report explains

General economic trends worldwide will affect the over-the-counter (OTC) pharma market from 2009 onwards, with both market restraints and opportunities present. In this new report – The Global OTC Pharmaceutical Market 2009-2024 – visiongain notes that Rx-to-OTC switching and the continuing importance of emerging pharma markets will drive OTC sales growth from 2009 onwards. Our forecasts reveal that the OTC pharma market will grow significantly next decade. This report explains where future OTC switching will occur, providing you with the information that you need to understand the current OTC market and its future prospects. The potential of this market remains significant, despite general economic uncertainty, visiongain asserts.

The Global OTC Pharmaceutical Market 2009-2024 examines all the major categories of OTC pharmaceuticals, including:
• Analgesics – for internal and external uses
• Cough, cold and allergy preparations
• Dermatology – including antifungal agents and hair-loss treatments
• Gastrointestinal drugs – including those for acid-related disorders, laxatives and anti-diarrhoea preparations
• Anti-obesity treatments
• Smoking cessation aids
• Others – including contraceptives, statins and erectile dysfunction areas.

Demographic trends, lifestyles changes and clinical advances are transforming medicine and creating opportunities for therapeutic areas and drug types in OTC pharma. Consumers are increasingly willing to self-medicate, for convenience and cost savings in particular. New regulations are changing OTC retail channels and sales processes, including the range of products on offer. Importantly, governments and healthcare providers are promoting self-medication, viewing the process as a tool to help contain healthcare expenditure. Therefore the OTC pharma market holds high potential for continued growth in both mature and emerging geographical markets.

Taking advantage of such opportunities will take considerable skill in a crowded and competitive marketplace. Competing with private labels, gaining regulatory approval for further OTC switches and harnessing Web 2.0 in advertising are all challenges that are assessed in this report, along with other aspects of the market.

Comprehensive analysis of the OTC market area

The Global OTC Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 100 tables and figures included. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to aid your work.

Why you should buy The Global OTC Pharmaceutical Market 2009-2024

Benefits from purchasing this report include:
• Your receiving a comprehensive appraisal of the OTC pharmaceutical market in 2008, including sales revenues and market shares for OTC categories, the top 10 companies and the leading OTC brands
• Your receiving sales forecasts and discussions covering the period 2009 to 2024, including the global OTC market, leading OTC brand forecasts, top OTC manufacturer forecasts and therapeutic category forecasts
• Your viewing sales forecasts for leading national OTC markets worldwide
• Your receiving coverage of OTC switching from 2009 onwards, with important developments that you cannot ignore
• Your viewing strengths, weaknesses, opportunities and threats facing the industry, with an emphasis on commercial drivers and restraints.

You can order this report today

The Global OTC Pharmaceutical Market 2009-2024 will provide you with a greater understanding of the expanding OTC market worldwide. What effect will the current downturn in consumer spending have on the OTC market? What are the OTC product market shares in each of the top-10 OTC companies? Which will be the most-important Rx-to-OTC switches in future? If you want to understand this important market, you can stay ahead by ordering this report today.

For more information, please visit :
http://www.aarkstore.com/reports/The-Global-OTC-Pharmaceutical-Market-2009-2024-32674.html
Or email us at press@aarkstore.com or call +919272852585

World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024

With Increasing Retinal Disease Prevalence and Unmet Clinical Needs – Which Drug will be the Next Lucentis?

The global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy are increasing due to rising numbers of older people worldwide. In addition, the world is facing a “diabetes epidemic”, with rapidly-increasing numbers of people with diabetes and diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and other retinal disorders. From 2009 to 2024, such treatments could repeat the commercial success that Lucentis achieved in the treatment of wet AMD. Our latest pharma report – World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 – examines prospects for the retinal disorder market over the next 15 years.

The rapid commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful novel treatments in the retinal disorders market. There is a clear market opportunity for other drugs to treat diabetic retinopathy, a condition for which there are currently no approved pharmacological treatments. Our analysts believe there are further commercial opportunities for new treatments for geographic atrophy (advanced dry AMD) and for wet AMD. There is a need for clear advantages over existing wet AMD therapies, for improved clinical outcomes and ease of dosing. This report analyses prospects there.

Comprehensive analysis of the market area

World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures and three full interviews with experts in the sector. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Why you should buy World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024

You will receive the following benefits when you order our report:
• You will receive sales forecasts for the global retinal disorder market, AMD market,diabetic retinopathy market and the market for other retinal disorders, together with sales forecasts for leading brands, from 2009 to 2024
• You will read expert opinion from key-opinion leaders in the retinal disorders pharmaceutical sector, including full transcripts of interviews not published elsewhere
• You will gain a comprehensive assessment of strengths, weakness, opportunities and threats for this sector, including discussion of market drivers and restraints
• You will receive an examination of the future prospects for Lucentis in the face of competition from off-label use of Avastin, with supporting market forecasts
• You will obtain a regional analysis of the AMD and diabetic retinopathy markets, with sales forecasts
• You will receive in-depth analyses of the pharmaceutical pipelines for AMD, diabetic retinopathy and other retinal disorders.

You can obtain this report today

World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 will provide you with the information that you need to understand this dynamic and rapidly-expanding sector. Which pipeline drug candidates are the ones to watch? When are they likely to reach the market? In which geographical regions are AMD and diabetic retinopathy complications forecasted to increase most in prevalence? This new report answers those questions and much more besides. Do you want to know more about this important market? You can stay ahead by ordering this report today

For more information, please visit :
http://www.aarkstore.com/reports/World-AMD-and-Diabetic-Retinopathy-Pharmaceutical-Market-2009-2024-32419.html
Or email us at press@aarkstore.com or call +919272852585

Chinese Pharmaceutical Market Outlook 2009-2024

In November 2008, China announced a major economic stimulus package, including $124bn to be spent on healthcare. These changes will have a major impact on the Chinese pharmaceutical landscape over the next 15 years, as the stimulus increases the number of clinics in rural areas, dissociates pharmacies from hospitals and promises healthcare coverage to 100% of the population by 2020. This report – Chinese Pharmaceutical Market Outlook 2009-2024 – analyses prospects for the pharma market and industry sector in China. This new study discusses market drivers and restraints such as production capacity, intellectual property rights and the high, fast-growing healthcare demands in China. Importantly, we provide detailed sales forecasting at the core of the analyses.

As both a large producer and consumer of a wide range of medicines, China is now a crucial player in the global pharmaceutical market and industry. China is still a challenging environment for foreign companies, investors and purchasers. Will the great potential benefits offered by China outweigh its drawbacks as a pharma market? Yes they will – but how and why? Read this report to find out.

China’s rising significance in the global pharma market will make it a vital market for international pharmaceutical companies to enter and expand. China’s efforts to reinvent its healthcare system will change the way pharmaceuticals are marketed and sold throughout the country. However, those changes will not take place immediately. What will happen first? For example, how will prescription of antibiotics change? Also, what impact will reported quality concerns and counterfeiting have on China’s pharmaceutical sector?

Comprehensive analysis of the Chinese pharma sector

Chinese Pharmaceutical Market Outlook 2009-2024 examines that sector critically, through a comprehensive review of information sources. This report provides detailed sales forecasts, discussions of developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 70 tables and figures and a full interview transcript from our survey. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Why you should buy Chinese Pharmaceutical Market Outlook 2009-2024

In this report you will receive the following benefits in particular:
• Sales forecasts for the overall Chinese pharma market from 2009 to 2024
• Sales forecasts for top-selling drug categories in that market from 2009 to 2024
• Comprehensive discussions to support the forecasts, including SWOT analysis and discussions of market drivers and restraints
• Forecasts for prescription drugs, branded drugs, generics, over-the-counter treatments and the clinical trials market in China
• Expert opinion from our original survey on emerging medical trends in China.

Crucial questions answered by this report:

This report answers important questions such as:
• What are the highest-selling drug types in China and how will their sales develop from 2009 onwards?
• How will the healthcare stimulus affect sales of diabetes medicines by 2014?
• Which companies are investing in China? What types of investments are they making?
• What is China’s scientific and technological expertise like?
• What domestic pharma companies are making promising developments, and what do their business models suggest about China’s pharma industry?
• What does China’s research and development landscape look like for pharma?
• Why is China such an important research and development environment for stem cells technologies?
• What is the generic drug penetration in China? How will market shares for original-branded and generic drugs change from 2009 onwards?
• Why are clinical trials moving to China, and how will that market develop?

You can obtain this report today

Chinese Pharmaceutical Market Outlook 2009-2024 will provide your company with the information it needs to understand this dynamic and rapidly-expanding pharma market. This report will give you the qualitative and quantitative information you need to assess the Chinese pharmaceutical market, to understand its likely future behaviour, including regulatory, social and developmental complexities.

For more information, please visit :
http://www.aarkstore.com/reports/Chinese-Pharmaceutical-Market-Outlook-2009-2024-32520.html
Or email us at press@aarkstore.com or call +919272852585